3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
NCT ID: NCT03791944
Last Updated: 2024-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2018-12-01
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar
NCT07137052
Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma
NCT04528394
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
NCT03175939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3DV+TPS/VARIAN
Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
3DV+TPS/VARIAN
Use imported 3DV+TPS to map targets and develop treatment plans
TPS/VARIAN
Use imported Varian TPS to map targets and develop treatment plans.
TPS / VARIAN
Use imported TPS to map targets and develop treatment plans
3DV+TPS/ Domestic accelerator
Use 3DV+TPS to map targets and develop treatment plans.
3DV + TPS / Domestic Accelerator
Use domestic 3DV+TPS to delineate target areas and develop treatment plans
TPS/ Domestic accelerator
Adopt domestic TPS hook target and develop treatment plan.
TPS / Domestic Accelerator
Use domestic TPS to map targets and develop treatment plans
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3DV+TPS/VARIAN
Use imported 3DV+TPS to map targets and develop treatment plans
TPS / VARIAN
Use imported TPS to map targets and develop treatment plans
3DV + TPS / Domestic Accelerator
Use domestic 3DV+TPS to delineate target areas and develop treatment plans
TPS / Domestic Accelerator
Use domestic TPS to map targets and develop treatment plans
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Reluctant to actively cooperate with the investigator;
3. Mergers with distant transfers;
4. Patients who have undergone head and neck surgery and radiotherapy;
5. Subjects who are affected by the disease who sign a written informed consent or follow the study procedure; or who are unwilling or unable to comply with the research requirements.
6. Those who have a history of psychotropic substance abuse who are unable to quit or have a mental disorder;
7. Participated in other clinical trials of anti-tumor drugs within 4 weeks before enrollment;
8. Pregnant or lactating women;
9. The investigator judges other conditions that may affect the clinical study and the outcome of the study.
Exclusion Criteria
2. The subject is aggravated or has a serious adverse reaction.
3. The subject himself requested to withdraw from the trial.
4. The patient is lost to follow-up or died.
5. The researcher believes that there is reason to withdraw
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xinqiao Hospital of Chongqing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianguo Sun
Deputy director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the second affiliated hospital of Army medical university
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XQonc-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.